Compare Republic Services Inc. Common Stock (RSG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Republic Services Inc. Common Stock vs TG Therapeutics Inc — how do they compare? Republic Services Inc. Common Stock trades at $225.58 (market cap $67.34B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: Republic Services Inc. Common Stock is far larger — about 8.1× TG Therapeutics Inc's market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RSG | TGTX | |
|---|---|---|
Market Cap | $67.34B | $8.32B |
Volume | 955,255 | 1,001,204 |
Sector | Industrials | Health |
52-Week High | $232.27 | $59.06 |
52-Week Low | $197.73 | $26.94 |
Enterprise Value | $81.53B | $8.52B |
Dividend Yield | 1.22% | — |
Typical Hold Time | — | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Republic Services Inc. Common Stock
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
